Journey Medical Common Stock Net 2020-2025 | DERM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Journey Medical common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Journey Medical common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$71.1B
Zoetis (ZTS)	$68.9B
Takeda Pharmaceutical (TAK)	$47.3B
Daiichi Sankyo, - (DSNKY)	$46B
BeOne Medicines - (ONC)	$32.9B
Sandoz Group AG (SDZNY)	$27.7B
Summit Therapeutics (SMMT)	$18.4B
Merck (MKKGY)	$16.3B
Shionogi (SGIOY)	$14.7B
United Therapeutics (UTHR)	$13.8B
Neurocrine Biosciences (NBIX)	$13.7B
Orion OYJ (ORINY)	$11.2B
IPSEN (IPSEY)	$11.2B
Madrigal Pharmaceuticals (MDGL)	$9.4B
Eisai (ESAIY)	$9.1B
Corcept Therapeutics (CORT)	$7.3B
Ionis Pharmaceuticals (IONS)	$6.8B
Stevanato Group S.p.A (STVN)	$6.8B
Grifols, S.A (GRFS)	$6.7B
Ono Pharmaceutical (OPHLF)	$5.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.4B
Soleno Therapeutics (SLNO)	$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.9B
Hypermarcas (HYPMY)	$2.8B
Procaps Group, S.A (PROCF)	$2.8B
NewAmsterdam Pharma (NAMS)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$2.1B